Luke Halpern, Assistant Editor

Shivang Joshi, MD, MPH, RPh, FAHS, discusses how Symbravo’s multi-mechanistic fixed-dose design may address gaps in acute migraine therapy for patients who do not respond to single-agent treatments.

In a phase 2 trial, the unimolecular agonist of GLP-1 and amylin induced major reductions in weight loss and hemoglobin A1c in patients with type 2 diabetes.

Examining Trends From Past Respiratory Virus Seasons Can Inform New Vaccination Strategies

Investigators determined a series of risk factors that can lead to complicated pneumococcal bacteremia, including older age and key comorbidities.

Post-pandemic, invasive pneumococcal disease cases rise among youth due to declining vaccination rates, highlighting urgent public health concerns.

A more significant association with cardiovascular disease (CVD) was observed among individuals with diabetes compared with those without.

Headache specialist Shivang Joshi, MD, MPH, RPh, FAHS, explains how the dual-mechanism combination of meloxicam and rizatriptan fits into acute migraine treatment.

A recent study reveals diverse long COVID trajectories, highlighting the need for further research to understand symptoms and recovery variability.

The FDA accelerates approval of sevabertinib for advanced non–small cell lung cancer, showcasing promising efficacy and manageable safety in clinical trials.

The investigational, oral PCSK9 inhibitor has the potential to significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia or patients with heterozygous familial hypercholesterolemia.

The SmartPhrase listed indications for PCV20 aligned with CDC guidelines and was incorporated into provider documentation, significantly improving vaccine uptake.

Young adults with high LDL-C levels face significant gaps in statin initiation and follow-up testing, highlighting urgent needs for improved cardiovascular care.

A series of predictors were associated with a higher likelihood of intensive care unit (ICU) admission and subsequently poor outcomes in patients with Streptococcus pneumoniae bacteremia.

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

Heart failure prevention can be integrated into health systems to optimize care.

At 3 and 9 months, inclisiran reduced low-density lipoprotein cholesterol in patients intolerant to statins or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors at rates comparable to those in placebo-controlled trials.

Integrating a pharmacist into multidisciplinary settings allowed for more thorough low-density lipoprotein cholesterol lowering in unique settings.

A bidirectional relationship was observed between long COVID and cardiovascular disease in survey results presented at IDWeek.

New data from AHA 2025 demonstrate the benefits of pharmacist-led hypertension management in reducing hemoglobin A1c (HbA1c) and blood pressure in minority patients with type 2 diabetes.

Knowledge of serotype prevalence and virulence can optimize the management of community-acquired pneumonia.

The move continues the push towards most favored nation (MFN) status, lowering the prices of glucagon-like peptide-1 (GLP-1s) drugs for Medicare recipients.

A genomic screening initiative identified patients harboring a familial hypercholesterolemia genetic variation and directed them toward LDL-C-lowering therapies, inducing meaningful reductions.

As an adjunct to depression treatment, lumateperone reduced depressive symptoms and improved quality of life.

Linaclotide has been approved to treat patients 7 years and older with irritable bowel syndrome with constipation, becoming the first treatment for this indication in this age group.

Adults in the United States are often infected by serotypes of Streptococcus pneumoniae unique to the pneumococcal 21-valent conjugate vaccine (PCV21) compared with those unique to PCV20.

Survivors of ischemic stroke had a lower risk of major adverse cardiovascular events (MACE) when achieving low levels of low-density lipoprotein cholesterol (LDL-C).

The FDA has approved doxecitine-doxribtimine powder for the treatment of patients with thymidine kinase 2 deficiency developing symptoms at or before the age of 12.

In children and adolescents, reinfection with COVID-19 increased the risk of worsened long COVID outcomes.

Richard Kovacs, MD, underscores the pharmacist’s role in educating patients about sodium reduction, monitoring blood pressure, and ensuring safe transitions to low-sodium oxybate therapy.

The 20-valent pneumococcal conjugate vaccine (PCV20) demonstrated higher vaccine effectiveness against invasive pneumococcal disease or all-cause pneumonia in cohorts of older adults.